Since specific expression of endosialin in the tumor stroma of many cancers and also tumor cells in sarcomas have been well demonstrated, we believe that other endosialin-specific antibodies or antibody-based therapeutic strategies deserve further investigation. This evidence concerns the gene CD248 and cancer.